Short Communication

Recent increase of breast cancer incidence among women under the age of forty

C Bouchardy*,1, G Fiorettia, HM Verkooijen1,2, G Vlastos3, P Schaefer3, J-F Delaloye4, I Neyroud-Caspar1, S Balmer Majno5, Y Wespi6, M Forni6, P Chappuis7, A-P Sappino7 and E Rapiti1

1Geneva Cancer Registry, Institute for Social and Preventive Medicine, University of Geneva, 55, bd de la Cluse, 1205 Geneva, Switzerland; 2Department of Community, Occupational and Family Medicine, National University of Singapore, 16 Medical Drive, 117597, Singapore; 3Senology and Surgical Gynecologic Oncology Unit, Department of Gynecology and Obstetrics, Geneva University Hospitals, Bd de la Cluse 32, 1205 Geneva, Switzerland; 4Department of Gynecology and Obstetrics, Vaud University Hospitals, CHUV, Rue du Bugnon 21, 1005 Lausanne, Switzerland; 5Division of Radio-Oncology, Geneva University Hospitals, Av, de la Roseraie 53, 1205 Geneva, Switzerland; 6Department of Gynecologic Oncology, Department of Gynecology and Obstetrics, Geneva University Hospitals, Bd de la Cluse 32, 1205 Geneva, Switzerland; 7Division of Oncology, Department of Medicine, Geneva University Hospitals, Rue Micheli-du-Crest 24, 1211 Geneva 14, Switzerland

Using data from the Geneva Cancer Registry, we found that in 2002–2004, breast cancer incidence in women aged 25–39 years increased by 46.7% per year (95% Cl: 7.1–74.0, P = 0.015), which surveillance or detection bias may not fully explain.

British Journal of Cancer (2007) 96, 1743–1746. doi:10.1038/sj.bjc.6603783 www.bjcancer.com

© 2007 Cancer Research UK

Keywords: breast cancer; young patients; trend; incidence rates; cancer registry; population-based study

RESULTS

For women aged 25–39 years, breast cancer rates were steady until 2002 and increased sharply thereafter, being 19.7 per 100 000 in 1995, rising to 53.9 per 100 000 in 2004 (Figure 1). Table 1 presents results of trend tests for the period 1995–2004 (middle columns)
Breast cancer in young women

and for the last 3-year period 2002–2004 (right column). The mean annual increase was 8.7% (95% CI: 2.8–15.0, \( P = 0.003 \)) over the whole period. The entire increase occurred in the last 3-year period (2002–2004) with a mean annual increase of 46.7% (95% CI: 7.1–100.8, \( P = 0.015 \)). Cancers at ages 25–39 represented 3.4% of all breast cancers in 1995 and 7.2% in 2004 (\( P = 0.032 \)). Also, since 1970 (when cancer registration started in Geneva) no such increase has been observed (data not shown). For the other age groups, incidence remained fairly stable, except for women aged 50–69 years among whom it increased at an average of 2.6% per year, from 1998 to 2002, when it stabilised (Table 1, Figure 1).

Table 1  Mean annual increase of breast cancer incidence rates by age group for the whole study period and for the last 3-year period and \( P \)-value for trend tests

| Age     | Incidence rates per 100 000 | Trend test for the whole study period 1995–2004\(^a\) | Trend test for the last 3-year period of the study 2002–2004\(^b\) |
|---------|---------------------------|--------------------------------------------------------|----------------------------------------------------------|
|         |                           | Mean annual increase (95% CI) \( P \)-value       | Mean annual increase (95% CI) \( P \)-value       |
| 25–39   | 19.7                      | +8.7 (2.8–15.0) \( P = 0.003 \)                     | +46.7 (7.1–100.8) \( P = 0.015 \)                     |
| 40–49   | 187.3                     | +2.6 (1.0–4.2) \( P = 0.001 \)                      | +11.0 (7.1–32.6) \( P = 0.247 \)                      |
| 50–69   | 312.4                     | −0.4 (−2.3–3.3) \( P = 0.756 \)                     | −4.0 (−11.7–8.3) \( P = 0.737 \)                      |
| 70–79   | 332.6                     | +0.9 (−2.5–4.5) \( P = 0.590 \)                     | +3.1 (−16.9–27.8) \( P = 0.781 \)                     |
| ≥80     | 330.7                     | −0.6 (−2.8–3.4) \( P = 0.700 \)                     | −1.7 (−4.4–1.0) \( P = 0.555 \)                      |

\( CI = \) confidence interval. \(^a\)Poisson regression testing trends of annual incidence rates during the period 1995–2004. \(^b\)Poisson regression testing trends of annual incidence rates during the period 2002–2004.

and for the last 3-year period 2002–2004 (right column). The mean annual increase was 8.7% (95% CI: 2.8–15.0, \( P = 0.003 \)) over the whole period. The entire increase occurred in the last 3-year period (2002–2004) with a mean annual increase of 46.7% (95% CI: 7.1–74.0%, \( P = 0.015 \)). Cancers at ages 25–39 represented 3.4% of all breast cancers in 1995 and 7.2% in 2004 (\( P = 0.032 \)). Also, since 1970 (when cancer registration started in Geneva) no such increase has been observed (data not shown). For the other age groups, incidence remained fairly stable, except for women aged 50–69 years among whom it increased at an average of 2.6% per year, from 1998 to 2002, when it stabilised (Table 1, Figure 1).

Table 2 shows tumour characteristics among women aged 25–39 years in 1995–2001 and 2002–2004. We found a significant increase in diagnoses diagnosed by MRI. In particular, 26% of breast cancers in young women were diagnosed by MRI in 1995–2001 compared with 48% in 2002–2004 (\( P = 0.006 \)). Screen-detected cancers increased non-significantly from 9 to 19%. The proportion of stage I cancers slightly decreased from 40 to 33%, whereas the proportion of stage II cancers remained relatively constant around 45%. Only three women had non-clinical T0 N0 tumours, one in the first and two in the second period. The mean tumour size remained unchanged over the whole study period, at 21 mm in 1995–2001 and 20 mm in 2002–2004 (\( P = 0.817 \)). We observed no increase in the proportion of young patients with a positive familial history of breast cancer.

DISCUSSION

In Geneva, breast cancer incidence in women aged <40 years has recently doubled. This increase may be partly explained by a higher screening frequency of younger women and better...
surveillance and recognition of familial risk factors. Improved tumour detection through advances in imaging techniques may also be involved, since in 1995–2001 less than 30% of breast cancer diagnoses in young women involved MRI compared with nearly 50% in 2002–2004 ($P = 0.006$).

Nevertheless, these detection biases seem unlikely to explain fully the observed incidence increase. Screening and improvement in diagnostic techniques should lead to a shift in stage distribution towards earlier stages, whereas in our population, this did not change significantly, and the proportion of clinically palpable tumours remained constant. The screening programme implemented in Geneva 10 years ago targets women aged 50–69 years, and screening for breast cancer in women <40 years is rare (Lutz et al., 2000). Furthermore, the proportion of patients reporting a positive family history has remained relatively stable around 30% between the two periods. We can also reasonably rule out an increase in fortuitous discovery of contralateral breast cancer as only two women were diagnosed with synchronous breast cancer in 2002 and 2003 respectively.

Although significant, our observation is based on only 63 patients diagnosed in 2002–2004, and should be interpreted with caution. With respect to any change in population estimates, the young resident female population grew smoothly over the study period, with no sudden increase in 2002–2004 (Figure 1). Among other cancer sites of women aged 25–39 years, we found a significant increase of melanoma (mean annual increase of 6.9%; 95% CI: 0.3–13.8, $P = 0.038$) starting early in the study period, but this is already a well-documented phenomenon in Switzerland (Association of Swiss Cancer Registries (ASCR), 2002). Other reasons should be explored to explain this increase in breast cancer incidence in younger women. Most known breast cancer risk factors, including nulliparity or later age at first full-term pregnancy, early menarche, dietary habits, alcohol intake, and lack of physical activity, apply at all ages. However, some other factors, such as family history of breast and/or ovarian cancer, in utero exposure, oral contraceptive use, smoking, and breast radiation are more relevant to young women (Yankaskas, 2005; Colditz et al., 2006).

In Geneva, prevalence of obesity has increased among adolescents and young females (Morabia and Costanza, 2005), but, in contrast to post-menopausal women, it appears to be protective against breast cancer in young women (Bouchardy et al., 1990; Magnusson et al., 2005; Michels et al., 2006). Smoking still seems to be increasing among women in Geneva and, compared with older women, young women begin smoking cigarettes at a much earlier age and are heavier smokers (Costanza et al., 2006).

### Table 2  Comparison of tumour assessment and characteristics of breast cancer patients aged <40 years before and after the increase began

| Patient and tumour characteristics | 1995–2001 | 2002–2004 | P-value for heterogeneity test |
|-----------------------------------|-----------|-----------|------------------------------|
| **Age at diagnosis**              |           |           |                              |
| 25–29 years                       | 6 (7)     | 6 (10)    | 0.523                        |
| 30–34 years                       | 32 (35)   | 17 (27)   |                              |
| 35–39 years                       | 54 (59)   | 40 (64)   |                              |
| **Method of detection**           |           |           |                              |
| Screening                         | 8 (9)     | 12 (19)   | 0.168                        |
| Breast self-examination           | 66 (72)   | 40 (64)   |                              |
| Symptoms, other                   | 18 (20)   | 11 (18)   |                              |
| **Diagnostic assessment**         |           |           |                              |
| Clinical status*                  | 81 (88)   | 58 (92)   | 0.419                        |
| Mammography or ultrasound*        | 80 (87)   | 56 (88)   | 0.719                        |
| MRI*                             | 24 (26)   | 30 (48)   | 0.006                        |
| **Family history**                |           |           |                              |
| Negative                          | 64 (70)   | 41 (65)   | 0.557                        |
| Positive                          | 28 (30)   | 22 (35)   |                              |
| **Stage**                         |           |           |                              |
| I                                | 37 (40)   | 21 (33)   | 0.673                        |
| II                               | 41 (45)   | 27 (43)   |                              |
| III                              | 7 (8)     | 9 (14)    |                              |
| IV                               | 4 (4)     | 3 (5)     |                              |
| Unknown                           | 3 (3)     | 3 (5)     |                              |
| **Histology**                     |           |           |                              |
| Ductal                           | 81 (88)   | 60 (95)   | 0.078                        |
| Lobular                          | 0 (0)     | 1 (2)     |                              |
| Other                            | 11 (12)   | 2 (3)     |                              |
| **Grade**                         |           |           |                              |
| I                                | 15 (16)   | 8 (13)    | 0.217                        |
| II                               | 33 (36)   | 33 (52)   |                              |
| III                              | 38 (41)   | 20 (32)   |                              |
| Unknown                           | 6 (7)     | 2 (3)     |                              |
| **Oestrogen receptor status**     |           |           |                              |
| Negative                         | 33 (36)   | 18 (29)   | 0.630                        |
| Positive                         | 56 (61)   | 43 (68)   |                              |
| Unknown                           | 3 (3)     | 2 (3)     |                              |
| **Progesterone receptor status**  |           |           |                              |
| Negative                         | 37 (40)   | 25 (40)   | 0.997                        |
| Positive                         | 52 (57)   | 36 (57)   |                              |
| Unknown                           | 3 (3)     | 2 (3)     |                              |
| **Total**                         | 92 (100)  | 63 (100)  |                              |

MRI = magnetic resonance imaging. *Binary variables classified as yes vs no.
No causal relation between breast cancer and smoking is generally accepted although any impact could be greater on young women (Miller et al., 2007). In this study, we can exclude an association with previous cancer treatment, given that only one woman was so affected (bilateral ovarian cancer).

In comparison, for Europe and the United States, we found no recent or sudden increase in breast cancer incidence among women under 40 years in the two main public-use cancer registry data sets, the Surveillance Epidemiology and End Results (SEER) and Cancer Incidence in Five Continents (CIF) (International Agency for Research on Cancer [IARC], 2002; National Cancer Institute [NCI], 2004). However, the latest available years were 1997 for CIF and 2003 for SEER.

In conclusion, we observed a significant increase in young breast cancer patients. At present, we cannot definitively rule out an increased surveillance and detection bias and we cannot confidently conclude a sustained increase. Careful surveillance of recent trends of breast cancer incidence is required for young women. If other population-based cancer registries confirm this trend, further research on breast cancer risk factors, including any acting in utero and early in life, would be indicated.

ACKNOWLEDGEMENTS

We thank Stina Blagojevic for her technical and editorial assistance, Arnaud Merglen for review and comments, Angela Grezet and the patients from the Comité Qualité de vie et Cancer du sein for their helpful feedback, and the Cancer registry team for providing data and support. We also thank the three reviewers of the JAMA for their very helpful comments on a previous version of the manuscript.

Dr HM Verkooijen was financially supported by PROSPER Grant No. 3233-069350 from the Swiss National Science Foundation.

REFERENCES

Association of Swiss Cancer Registries (ASCR) 2002 Available from: URL: www.ascr.ch [cited 2007]
Bouchardy C (1997) Switzerland, Geneva. In: Cancer Incidence in Five Continents, vol. VII. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds). 666–669. Lyon: International Agency for Research on Cancer.
Bouchardy C, Lé MG, Hill C (1990) Risk factors for breast cancer according to age at diagnosis in a French case-control study. J Clin Epidemiol 43(3): 267–275
Colditz GA, Baer HJ, Tamimi RM (2006) Breast cancer. In: Cancer Epidemiology and Prevention Schottenfeld D, Fraumeni Jr JF (eds). 995–1012. New York: Oxford University Press
Costanza MC, Salamun J, Lopez AD, Morabia A (2006) Gender differentials in the evolution of cigarette smoking habits in a general European adult population from 1993–2003. BMC Public Health 6: 130
Francis B, Green M, Payne CD (1993) GLIM 4 The Statistical System for Generalized Linear Interactive Modelling. Oxford: Oxford University Press
International agency for research on cancer (IARC) (2002) Cancer Mondial. Available from URL: http://www-dep.iarc.fr/ [cited 2007]
International Union against Cancer (UICC) (eds). (1992) TNM Classification of Malignant Tumours. Berlin: Springer Verlag
Lutz JM, Reith-Chatton J, Fioretta G, Cerny V, Bouchardy C (2000) Surveys on mammography frequency in Geneva. J Med Screen 7: 111–113
Magnusson CM, Roddam AW, Pike MC, Chilvers C, Crossley B, Hermon C, McPherson K, Peto J, Vessey M, Beral V (2005) Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women. Br J Cancer 93: 817–824
Michels KB, Terry KL, Willett WC (2006) Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 166: 2395–2402
Miller MD, Marty MA, Broadwin R, Johnson KC, Salmon AG, Winder B, Steinmaus C (2007) The association between exposure to environmental tobacco smoke and breast cancer: A review by the California Environmental Protection Agency. Prev Med 44 (2): 93–106
Morabia A, Costanza MC (2005) The obesity epidemic as harbinger of a metabolic disorder epidemic: trends in overweight, hypercholesterolemia, and diabetes treatment in Geneva, Switzerland, 1993–2003. Am J Public Health 95: 632–635
National Cancer Institute (NCI) 2004 Surveillance, Epidemiology and End Results SEER. Available from: URL: http://www.seer.cancer.gov/ [cited 2007]
World Health Organization (WHO) (1976) ICD-O International Classification of Diseases for Oncology. Geneva: World Health Organization
Yankaskas BC (2005) Epidemiology of breast cancer in young women. Breast Dis 23: 3–8